Filtered By:
Condition: Hemorrhagic Stroke
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 553 results found since Jan 2013.

Impact of double‐blind versus open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for haemorrhagic stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 9, 2013 Category: Hematology Authors: Jean‐Christophe Lega, Patrick Mismetti, Michel Cucherat, Thomas Fassier, Laurent Bertoletti, Céline Chapelle, Silvy Laporte Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Impact of double‐blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for hemorrhagic stroke.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: J.‐C. Lega, P. Mismetti, M. Cucherat, T. Fassier, L. Bertoletti, C. Chapelle, S. Laporte Tags: Original Article Source Type: research

Novel Oral Anticoagulants in Cardiovascular Disease
Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis of venous thromboembolism. The OAC halts the coagulation by different mechanisms. Until recently, the only option was the vitamin K antagonists (VKAs), but their inherent limitations have promoted the development of novel oral anticoagulants (NOACs), which may offer efficacious and safer alternatives. Patients...
Source: Journal of Cardiovascular Pharmacology and Therapeutics - December 17, 2013 Category: Cardiology Authors: Gallego, P., Roldan, V., Lip, G. Y. H. Tags: Cardiovascular Pharmacology Core Reviews Source Type: research

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
CONCLUSIONS: DTIs were as efficacious as VKAs for the composite outcome of vascular death and ischaemic events and only the dose of dabigatran 150 mg twice daily was found to be superior to warfarin. DTIs were associated with fewer major haemorrhagic events, including haemorrhagic strokes. Adverse events that led to discontinuation of treatment occurred more frequently with the DTIs. We detected no difference in death from all causes. PMID: 24677203 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 27, 2014 Category: Journals (General) Authors: Salazar CA, Del Aguila D, Cordova EG Tags: Cochrane Database Syst Rev Source Type: research

Apixaban In Patients With Atrial Fibrillation: Patient Characteristics Of The Latin America Cohort From A Multinational Clinical Trial
Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Avezum, MC Bahit, JA Hermosillo, FL Zanetti, P Perafan, A Juarez-Garcia, C Vulcano, LA Cubillos, BM Korenblat Donato Source Type: research

Individualised approaches to thrombo-prophylaxis in atrial fibrillation
Publication date: Available online 11 November 2015 Source:American Heart Journal Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in adults over 55 years of age is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart-rate control, and heart-rhythm control comprise the three main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antag...
Source: American Heart Journal - November 12, 2015 Category: Cardiology Source Type: research

Non Vitamin K Oral Anticoagulants versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments yield Novel Insights
ConclusionsFor the primary‐outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced haemorrhagic‐stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential haemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary‐outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 4, 2016 Category: Cardiology Authors: Cyrus R Kumana, Bernard M Y Cheung, David C W Siu, Hung‐Fat Tse, Ian J Lauder Tags: Unsolicited Review Source Type: research

Individualized approaches to thromboprophylaxis in atrial fibrillation
Publication date: March 2016 Source:American Heart Journal, Volume 173 Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in persons older than 55 years is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart rate control, and heart rhythm control comprise the 3 main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism, and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antagonist such as ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Effective practical management of patients with atrial fibrillation when using new oral anticoagulants.
Authors: Cox JL Abstract Practical management of stroke prevention in patients with non-valvular atrial fibrillation (AF) requires physicians to find the optimal balance between maximizing prevention of ischaemic stroke and minimizing the risk of bleeding. Vitamin K antagonists have traditionally been used for stroke prevention in patients with AF; however, they have been associated with increased risk of bleeding, particularly intracranial haemorrhage. New oral anticoagulants (OACs) have shown similar efficacy to the vitamin K antagonist warfarin but with a reduced risk of bleeding, particularly life-threatening b...
Source: Annals of Medicine - February 18, 2016 Category: Internal Medicine Tags: Ann Med Source Type: research

Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
ConclusionsFor the primary outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced hemorrhagic stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential hemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Cyrus R. Kumana, Bernard M.Y. Cheung, David C.W. Siu, Hung‐Fat Tse, Ian J. Lauder Tags: Unsolicited Review Source Type: research

Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.
Authors: Marín F, Anguita Sánchez MP, Sanmartín Fernández M Abstract INTRODUCTION: Patients with atrial fibrillation have an increased risk for stroke, systemic embolism and cardiovascular events, including myocardial infarction and cardiovascular death. However, the majority of studies that have analyzed the efficacy of anticoagulants have been focused only on their effects on the risk of stroke. Areas covered: The available evidence about the association between atrial fibrillation and cardiovascular disease as well as the effects of oral anticoagulation on cardiovascular death and myocardial infarction, with...
Source: Expert Opinion on Pharmacotherapy - December 8, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Comparing the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in the Elderly Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
CONCLUSIONS: Compared to warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata. Overall, the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, being most marked in the most elderly. PMID: 31809694 [PubMed - as supplied by publisher]
Source: Chest - December 2, 2019 Category: Respiratory Medicine Authors: Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GYH, Chen SA Tags: Chest Source Type: research

Direct oral anticoagulants in chronic kidney disease: an update
Purpose of review Direct oral anticoagulants (DOACs) are variably eliminated by the kidneys rendering their use potentially problematic in patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment. Recent findings Both observational and limited randomized trial data for DOACs compared with no treatment or with warfarin for patients with atrial fibrillation on maintenance dialysis were recently published. In a randomized trial in patients on hemodialysis, there was no significant difference in vascular calcification between patients who received rivaroxaban with or without vitamin K2 or vi...
Source: Current Opinion in Nephrology and Hypertension - August 1, 2020 Category: Urology & Nephrology Tags: PHARMACOLOGY AND THERAPEUTICS: Edited by Sankar D. Navaneethan Source Type: research

Safety of antithrombotic therapy in East Asian patients
In conclusion, further investigations are necessary to clarify the specific conditions where the risk of serious bleeding events in East Asian patients differ substantially compared to the global. In addition, further understanding of the mechanisms causing the different bleeding response in specific conditions in East Asian is awaited.
Source: Internal and Emergency Medicine - March 8, 2021 Category: Emergency Medicine Source Type: research

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
CONCLUSION: Dabigatran, rivaroxaban, and apixaban appear to be superior to warfarin in both efficacy and safety in Asians with non-valvular AF.PMID:33968307 | PMC:PMC8069517 | DOI:10.4330/wjc.v13.i4.82
Source: World Journal of Cardiology - May 10, 2021 Category: Cardiology Authors: Wei-Jia Li Paraschos Archontakis-Barakakis Leonidas Palaiodimos Dimitrios Kalaitzoglou Lazaros Tzelves Apostolos Manolopoulos Yu-Chiang Wang Stefanos Giannopoulos Robert Faillace Damianos G Kokkinidis Source Type: research